Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Inventiva ( (IVA) ) just unveiled an update.
On October 30, 2025, Inventiva S.A. announced the mailing of proxy cards and voting instructions to its American Depositary Shareholders for the upcoming Ordinary and Extraordinary General Meeting scheduled for November 27, 2025, in Paris. This meeting will address several key proposals, including the approval of compensation policies, settlement agreements, and authorizations related to share options and capital increases. These decisions could significantly impact the company’s governance and financial strategies, influencing stakeholder interests and company operations.
The most recent analyst rating on (IVA) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Inventiva stock, see the IVA Stock Forecast page.
Spark’s Take on IVA Stock
According to Spark, TipRanks’ AI Analyst, IVA is a Neutral.
Inventiva’s overall stock score is primarily impacted by its poor financial performance, characterized by persistent losses and negative margins. The technical analysis further indicates a bearish trend, while the valuation metrics highlight ongoing financial challenges. The absence of earnings call data and corporate events does not influence the score.
To see Spark’s full report on IVA stock, click here.
More about Inventiva
Inventiva S.A. operates in the biopharmaceutical industry, focusing on the development of oral small molecule therapies for the treatment of fibrotic, inflammatory, and metabolic diseases. The company is particularly known for its innovative research in conditions like non-alcoholic steatohepatitis (NASH) and mucopolysaccharidosis (MPS).
Average Trading Volume: 151,485
Technical Sentiment Signal: Buy
Current Market Cap: $637.4M
For a thorough assessment of IVA stock, go to TipRanks’ Stock Analysis page.